Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort.

"further details of lpa methods are given in supplementary data s1 available at rheumatology online."

"Disclosure statement : S.D. has received grant support from UCB and Eli Lilly. A.L.H. has received grant support from Gesynta; consultancy fees from Arena, Boehringer-Ingelheim, Camurus, CSL-Behring, and Gesynta and speaker fees from Janssen. H.C. has received grant support from Eli Lilly and UCB; consulting fees from Novartis, Eli Lilly, Orphazyme and AstraZeneca and has been a speaker for UCB and Biogen. I.N.B. has received grant support from Genzyme/Sanofi, GlaxoSmithKline, Roche and UCB; consulting fees from AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck Serono and UCB and was a speaker for AstraZeneca, GlaxoSmithKline and UCB. B.P. has received grant support from Genzyme/Sanofi and GlaxoSmithKline, honoraria from Fresenius-Kabi and AbbVie and was a speaker for Eli Lilly and Roche."

"Funding S.D. is an MRC Clinical Training Fellow based at the University of Manchester supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council (award MR/N025989/1), Roche Pharma, Eli Lilly, UCB Pharma, Novartis, the University of Liverpool and the University of Manchester. H.C. and A.H. are supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. I.N.B. is a National Institute for Health Research (NIHR) Senior Investigator Emeritus and is funded by the NIHR Manchester Biomedical Research Centre. B.P. is supported by the NIHR Manchester Biomedical Research Centre and NIHR Manchester Clinical Research Facility. Disclosure statement: S.D. has received grant support from UCB and Eli Lilly. A.L.H. has received grant support from Gesynta; consultancy fees from Arena, Boehringer-Ingelheim, Camurus, CSL-Behring, and Gesynta and speaker fees from Janssen. H.C. has received grant support from Eli Lilly and UCB; consulting fees from Novartis, Eli Lilly, Orphazyme and AstraZeneca and has been a speaker for UCB and Biogen. I.N.B. has received grant support from Genzyme/Sanofi, GlaxoSmithKline, Roche and UCB; consulting fees from AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck Serono and UCB and was a speaker for AstraZeneca, GlaxoSmithKline and UCB. B.P. has received grant support from Genzyme/Sanofi and GlaxoSmithKline, honoraria from Fresenius-Kabi and AbbVie and was a speaker for Eli Lilly and Roche."